AstraZeneca's phase III trial of AZD1222 demonstrates significant vaccine efficacy of 79% at prevent


The AstraZeneca US phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic Covid─19 and 100% efficacy ... Lees verder

Bron: Pharmamarketeer
Geplaatst: 29 mrt 2021 - 14:10